CELLINK completes the acquisition of Scienion AG
As announced on August 19, 2020, CELLINK AB (publ) (“CELLINK”) entered into an agreement to acquire the precision dispensing company Scienion AG. CELLINK has on this day completed the acquisition of all Scienion-shares.
The purchase price, on cash- and debt-free basis, amounted to 80 MEUR, of which 40 MEUR was paid in 2,814,032 newly issued shares of series B in CELLINK at a price of 146.6 SEK per share (the “Consideration Shares”) and the reminder in cash. The Consideration Shares are expected to be registered by the Swedish Companies Registration Office during the month of September and will correspond to approximately 6 percent of the share capital and approximately 4.6 percent of the votes in CELLINK.
"With Scienion’s revolutionary technology platforms and brilliant team we will streamline bioprinting and sample preparation workflows, while enhancing our presence in the clinical field, a strategy that is well aligned with our long-term vision. Together with Dispendix, cytena, Cellenion, and Scienion, we will now be better positioned to offer complete bioprinting and single cell printing solutions, stretching all the way from early stage R&D products to advanced manufacturing systems. Our combined, complimentary product portfolio will position CELLINK as a market leader in bioprinting, single cell handling, and precision dispensing." Erik Gatenholm, CEO
For further information on the acquisition and about Scienion AG, please see the press release which was published on August 19, 2020.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
The information was submitted for publication, through the agency of the contact persons set out above, on September 2, 2020 at 08:58 p.m. (CEST).
CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.
Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.